NSAID ‐exacerbated respiratory disease (N‐ ERD ) is a chronic eosinophilic, inflammatory
disorder of the respiratory tract occurring in patients with asthma and/or chronic rhinosinusitis …

Novel therapies such as type 2 targeting biologics are emerging treatment options for
patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely …

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival and
degranulation of eosinophils. Indeed, during the last years significant advances have been …

In less than half a century, allergy, originally perceived as a rare disease, has become a
major public health threat, today affecting the lives of more than 60 million people in Europe, …

The review examines recent advances in the biology of eosinophils and how targeting the
interleukin-5 pathway might offer benefit to some patients with severe asthma, EGPA, and …

Background Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional …

…Enrico Hefflerreports participation to advisory boards and personal fees from AstraZeneca,
Sanofi, GSK, Novartis, Circassia, Nestlè Purina, Boheringer Ingheleim, Valeas, outside the …

Approximately 5%–10% of asthmatic patients worldwide suffer from severe asthma. Experimental
and clinical studies have demonstrated that IL-13 is an important cytokine in chronic …

Inflammation, structural, and functional abnormalities within the airways are key features of
asthma. Although these processes are well documented, their expression varies across the …

The enigmatic eosinophil has emerged as an exciting component of the immune system,
involved in a plethora of homeostatic and inflammatory responses. Substantial progress has …